[{"from": "human", "value": "Please give me some details about this molecule. [C][C][C][Ring1][Ring1][C][N][C][C][C@][C][C][=Branch1][C][=O][C][C][C@][Ring1][#Branch1][Branch2][Ring1][=Branch2][C@H1][Ring1][O][C][C][=C][Ring1][O][C][=Branch1][=N][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=Branch1][C][=O][N][O][O]"}, {"from": "gpt", "value": "The molecule is an effective atypical antipsychotic that, like other antipsychotics, is associated with weight gain, metabolic dysfunction, and increased risk of type II diabetes. Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent \u03bc-opioid receptor antagonism, higher oral bioavailability, and a longer half-life, making it an attractive candidate for oral dosing. Although antipsychotic-induced weight gain is incompletely understood, it is thought that the opioid system plays a key role in feeding and metabolism, such that opioid antagonism may be expected to ameliorate these negative effects. Samidorphan has been shown in animal models and clinical trials to ameliorate [olanzapine]-induced weight gain and metabolic dysfunction.  Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI\u2122 by Alkermes Inc."}]